Zipalertinib

Zipalertinib
Clinical data
Other names	CLN-081, TAS-6417, TPC-064
Identifiers
	IUPAC name N-[(8S)-4-amino-6-methyl-5-quinolin-3-yl-8,9-dihydropyrimido[5,4-b]indolizin-8-yl]prop-2-enamide;
CAS Number	1661854-97-2;
PubChem CID	117918742;
ChemSpider	71117518;
UNII	T4YMU8TW9H;
KEGG	D93895;
ChEMBL	ChEMBL4650281;
Chemical and physical data
Formula	C23H20N6O
Molar mass	396.454 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C;
	InChI InChI=InChI=1S/C23H20N6O/c1-3-18(30)28-16-8-13(2)21-19(15-9-14-6-4-5-7-17(14)25-10-15)20-22(24)26-12-27-23(20)29(21)11-16/h3-10,12,16H,1,11H2,2H3,(H,28,30)(H2,24,26,27)/t16-/m0/s1; Key:MKCYPWYURWOKST-INIZCTEOSA-N;

Zipalertinib is an investigational new drug that is being evaluated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly exon 20 insertion mutations.^[1]^[2]^[3]

References

^ "Zipalertinib - Cullinan Therapeutics". AdisInsight. Springer Nature Switzerland AG.
^ Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, et al. (August 2018). "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations" (PDF). Molecular Cancer Therapeutics. 17 (8): 1648–1658. doi:10.1158/1535-7163.MCT-17-1206. PMID 29748209.
^ Seo D, Lim JH (May 2024). "Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer". International Journal of Molecular Sciences. 25 (11): 5917. doi:10.3390/ijms25115917. PMC 11172945. PMID 38892105.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.